AURKA and familial pancreatic carcinoma: In addition, although the in vivo efficacy of these novel dual PDK1/Aurora A kinase inhibitors appears to be overly limited by these limitations, their ability to reduce both anchorage dependent and independent growth of a panel of pancreatic cancer cell lines without affecting immortalized pancreatic cells in vitro is encouraging nonetheless.